While the company is no longer enjoying the benefit of enormous sales for its COVID treatment Veklury, Gilead is still doing very nicely, thank you very much.
Last year GSK made a strategic move to focus solely on biopharma, and it is already realizing the benefits of a more targeted business.
J&J is heading into the remainder of 2023 with a new look and a revised outlook.
For better or worse, Lilly’s Mounjaro has captured the world’s attention.
While the shooting star Lagevrio pushed Merck’s top line to nearly $60 billion in 2022, the rest of the company’s portfolio is catching up.
Following a year of transformation, Novartis is laser-focused on its goals.
Pfizer’s mRNA vaccine, Comirnaty, was the company’s highest-selling product once again, but leaders are looking to the Seagen acquisition for future growth.
Moving forward, Roche is prioritizing and reimagining its R&D strategy to build a stronger portfolio.
In 2022, Sanofi’s adherence to its strategy has yielded an expanded pipeline, greater sales and net income, and progress in the use of artificial intelligence.
Takeda’s top five brands all grew substantially in FY 2022, none by less than 30 percent.
